国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
9期
1221-1223
,共3页
胡家柱%谭洁霞%何艳%李济时%黎益华%曹小龙
鬍傢柱%譚潔霞%何豔%李濟時%黎益華%曹小龍
호가주%담길하%하염%리제시%려익화%조소룡
艾迪注射液%鼻咽癌
艾迪註射液%鼻嚥癌
애적주사액%비인암
AiDi%Nasopharynx cancer
目的 探讨艾迪等中药制剂在鼻咽癌放疗中的作用.方法 随机将鼻咽癌患者分为两组,实验组在放疗同期同时给予静脉滴注艾迪注射液,对照组仅予以放疗及化疗.放疗中期及放疗结束后分别检查实验组及对照组的鼻咽部MR及EB病毒指标、血常规、KPS评分、体重等,并采用SPSS16.0软件进行统计学分析.结果 实验组及对照组在降低EA-IgA(治疗后1周及2周P值分别为0.036、0.034)、VCA-IgA(治疗后1周及2周P值分别为0.01、0.01)及DNA拷贝(治疗后1周及2周P值分别为0.01、0.005)上存在统计学差异,CR率等无明显统计学差异.结论 艾迪注射液能有效降低EBV病毒DNA拷贝及滴度,但并不能提高肿瘤缓解率.
目的 探討艾迪等中藥製劑在鼻嚥癌放療中的作用.方法 隨機將鼻嚥癌患者分為兩組,實驗組在放療同期同時給予靜脈滴註艾迪註射液,對照組僅予以放療及化療.放療中期及放療結束後分彆檢查實驗組及對照組的鼻嚥部MR及EB病毒指標、血常規、KPS評分、體重等,併採用SPSS16.0軟件進行統計學分析.結果 實驗組及對照組在降低EA-IgA(治療後1週及2週P值分彆為0.036、0.034)、VCA-IgA(治療後1週及2週P值分彆為0.01、0.01)及DNA拷貝(治療後1週及2週P值分彆為0.01、0.005)上存在統計學差異,CR率等無明顯統計學差異.結論 艾迪註射液能有效降低EBV病毒DNA拷貝及滴度,但併不能提高腫瘤緩解率.
목적 탐토애적등중약제제재비인암방료중적작용.방법 수궤장비인암환자분위량조,실험조재방료동기동시급여정맥적주애적주사액,대조조부여이방료급화료.방료중기급방료결속후분별검사실험조급대조조적비인부MR급EB병독지표、혈상규、KPS평분、체중등,병채용SPSS16.0연건진행통계학분석.결과 실험조급대조조재강저EA-IgA(치료후1주급2주P치분별위0.036、0.034)、VCA-IgA(치료후1주급2주P치분별위0.01、0.01)급DNA고패(치료후1주급2주P치분별위0.01、0.005)상존재통계학차이,CR솔등무명현통계학차이.결론 애적주사액능유효강저EBV병독DNA고패급적도,단병불능제고종류완해솔.
Objective To investigate the efficacy of AiDi for nasopharynx cancer.Methods Patients with nasopharynx cancer were randomly assigned to experiment group and control group.And the experiment group were treated with AiDi and rediochemotherapy while the control group took only radiochemotheapy.After the whole therapy,the MRI of nasopharynx,EBV-DNA,blood test,weight were tested.And the data were analyzed with SPSS 16.0 software.Results The EBV-DNA in the experiment group were obviously reduced,but there was no statistical difference in CR.Conclusions AiDi could reduce the EBV-DNA and EBV Virus titer,but it can' t improve the remission rate.